{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:11:04Z","timestamp":1769731864548,"version":"3.49.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004488","name":"Croatian Science Foundation","doi-asserted-by":"publisher","award":["IP-2022-10-8228"],"award-info":[{"award-number":["IP-2022-10-8228"]}],"id":[{"id":"10.13039\/501100004488","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013291","name":"European Observation Network for Territorial Development and Cohesion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013291","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jpba.2025.116664","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T10:04:18Z","timestamp":1736071458000},"page":"116664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Differentiation of the chronic lymphocytic leukemia response to ibrutinib and acalabrutinib treatment by single-cell MALDI-TOF MS imaging"],"prefix":"10.1016","volume":"255","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2180-7789","authenticated-orcid":false,"given":"Ivana","family":"Markovi\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Luki\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maja","family":"Luki\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9624-0272","authenticated-orcid":false,"given":"Ema","family":"Pavi\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6993-7801","authenticated-orcid":false,"given":"Stefan","family":"Mr\u0111enovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Kotris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Branko","family":"Dmitrovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u017deljko","family":"Debeljak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2025.116664_bib1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.jpba.2025.116664_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s11523-021-00857-8","article-title":"Bruton tyrosine kinase inhibitors in B-Cell malignancies: their use and differential features","volume":"17","author":"Shirley","year":"2021","journal-title":"Target Oncol."},{"key":"10.1016\/j.jpba.2025.116664_bib3","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1124\/jpet.117.242909","article-title":"Acalabrutinib (ACP-196): a covalent Bruton tyrosine kinase inhibitor with a differentiated selectivity and in vivo potency profile","volume":"363","author":"Barf","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jpba.2025.116664_bib4","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"Bruton tyrosine kinase inhibitors: present and future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J."},{"key":"10.1016\/j.jpba.2025.116664_bib5","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.tips.2024.06.006","article-title":"BTK inhibitors: past, present, and future","volume":"45","author":"Cool","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jpba.2025.116664_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1124\/dmd.114.061424","article-title":"The role of extrahepatic metabolism in the pharmacokinetics of the targeted covalent inhibitors afatinib, ibrutinib, and neratinib","volume":"43","author":"Shibata","year":"2015","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2025.116664_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3324\/haematol.2017.176164","article-title":"In vitro and in vivo evidence for uncoupling of B-cell receptor internalization and signaling in chronic lymphocytic leukemia","volume":"103","author":"Coulter","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jpba.2025.116664_bib8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/dmd.118.084459","article-title":"Bioavailability, biotransformation, and excretion of the covalent Bruton tyrosine kinase inhibitor acalabrutinib in rats, dogs, and humans","volume":"47","author":"Podoll","year":"2019","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2025.116664_bib9","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3324\/haematol.2022.282466","article-title":"Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia","volume":"109","author":"Rey-Barroso","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jpba.2025.116664_bib10","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1515\/cclm-2019-0858","article-title":"Cellular resolution in clinical MALDI mass spectrometry imaging: the latest advancements and current challenges","volume":"58","author":"\u0160\u010dup\u00e1kov\u00e1","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jpba.2025.116664_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119758","article-title":"Metabolic profiling of CD19+\u2009cells in chronic lymphocytic leukemia by single-cell mass spectrometry imaging","volume":"561","author":"Markovi\u0107","year":"2024","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2025.116664_bib12","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association. Declaration of Helsinki, Ethical Principles for Medical Research Involving Human Subjects","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.jpba.2025.116664_bib13","unstructured":"R Core Team, R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, 2023 \u3008https:\/\/www.R-project.org\/\u3009."},{"key":"10.1016\/j.jpba.2025.116664_bib14","doi-asserted-by":"crossref","first-page":"D622","DOI":"10.1093\/nar\/gkab1062","article-title":"HMDB 5.0: the human metabolome database for 2022","volume":"50","author":"Wishart","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jpba.2025.116664_bib15","doi-asserted-by":"crossref","first-page":"17447","DOI":"10.1002\/anie.202007315","article-title":"Morphometric cell classification for single-cell MALDI-mass spectrometry imaging","volume":"59","author":"\u0160\u010dup\u00e1kov\u00e1","year":"2020","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jpba.2025.116664_bib16","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2114365119","article-title":"Mass spectrometry imaging to explore molecular heterogeneity in cell culture","volume":"119","author":"Bien","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.jpba.2025.116664_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687458","article-title":"Targeting Bruton's tyrosine kinase in CLL","volume":"12","author":"Ahn","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jpba.2025.116664_bib18","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","article-title":"Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells","volume":"23","author":"Patel","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jpba.2025.116664_bib19","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/leu.2017.321","article-title":"Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy","volume":"32","author":"Patel","year":"2018","journal-title":"Leukemia"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525000056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708525000056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T12:17:36Z","timestamp":1769689056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708525000056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"alternative-id":["S0731708525000056"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116664","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Differentiation of the chronic lymphocytic leukemia response to ibrutinib and acalabrutinib treatment by single-cell MALDI-TOF MS imaging","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2025.116664","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116664"}}